Media Articles Related to Lupron Depot (Leuprolide)
Is There a Better Way to Diagnose Endometriosis?
Source: Medscape Pathology & Lab Medicine Headlines [2016.10.20]
Dr Peter Kovacs reviews the research on using CA125 to aid the diagnosis of endometriosis.
Positive pivotal Phase 3 data announced demonstrating investigational Elagolix reduced endometriosis-associated pain
Source: Clinical Trials / Drug Trials News From Medical News Today [2016.10.20]
AbbVie, a global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc.
Source: MedicineNet Ectopic Pregnancy Specialty [2016.10.07]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/7/2016 12:00:00 AM
Endometriosis Symptoms, Stages, Treatment
Source: MedicineNet Endometriosis Specialty [2016.08.04]
Title: Endometriosis Symptoms, Stages, Treatment
Created: 3/3/2011 3:43:00 PM
Last Editorial Review: 8/4/2016 12:00:00 AM
Published Studies Related to Lupron Depot (Leuprolide)
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. [2011.09]
PURPOSE: We investigated the efficacy and safety of degarelix treatment and the effects of switching from leuprolide to degarelix in an ongoing extension study with a median 27.5-month followup of a pivotal 1-year prostate cancer trial... CONCLUSIONS: Data support the statistically significant prostate specific antigen progression-free survival benefit for degarelix over leuprolide seen during year 1 and the use of degarelix as first line androgen deprivation therapy as an alternative to a gonadotropin-releasing hormone agonist. Copyright (c) 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. [2011.06.30]
We performed a randomized trial to compare IVF outcomes in 54 poor responder patients undergoing a microdose leuprolide acetate (LA) protocol or a GnRH antagonist protocol incorporating a luteal phase E(2) patch and GnRH antagonist in the preceding menstrual cycle.
Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. [2011.06]
The aim of the study was to compare the onset, incidence and frequency/intensity of hot flushes during androgen-deprivation therapy with a gonadotropin-releasing hormone antagonist (GnRH) blocker versus an agonist using data from a randomized Phase 3 clinical trial...
Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. [2011.04]
OBJECTIVE: To compare the efficacy of leuprolide and continuous oral contraceptives in the treatment of endometriosis-associated pain...
Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. [2010.11]
OBJECTIVE: To determine whether insulin sensitizers lower androgen levels and whether androgen suppression improves insulin resistance in nondiabetic postmenopausal women... They confirm that treatment of insulin resistance decreases T production in this population and demonstrate that pharmacologic lowering of T does not affect insulin resistance.
Clinical Trials Related to Lupron Depot (Leuprolide)
Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty [Completed]
The purpose of this extension study is to determine if leuprolide acetate (11. 25 mg and 30
mg) is safe in treating children with Central Precocious Puberty over a longer period of
time (36 months).
Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation [Recruiting]
- One way to treat certain cancers of the blood and immune system is to give a patient
stem cells from the bone marrow of a donor whose genes are very similar but not
identical to the patient s. One problem with these transplants is that the new immune
cells may not work as well in the recipient as they did in the donor. The result may be
that the immune system will not work as well. This can increase the risk of severe
infections and other complications.
- Researchers are studying the use of drugs that lower hormone levels and may allow the
immune system to recover in a way that improves white blood cell function. In this
study they will be looking at the drug lupron, a drug that lowers estrogen or
testosterone levels, to see if it might improve the function of the newly transplanted
- To determine whether lupron improves immune system function after bone marrow
transplantation from a donor with similarities in their immune cells (matched to each
- To evaluate the effectiveness of a nuclear medicine test with a radiotracer drug FLT in
imaging studies. FLT will be used to image the immune system function in patients who
have received bone marrow from the donor.
- People between 15 (or as young as 9 in those who have gone through puberty) and 40
years of age. These patients must have acute myelogenous leukemia, acute lymphocytic
leukemia, or high-risk myelodysplastic syndrome. They must also be eligible for a bone
- Genetically similar donors for the patients who are eligible for a transplant.
- People taking part in the study will be screened with a physical examination, medical
history, blood and urine tests, and imaging studies. Patients who are not in remission
or who require a bone marrow donor search may receive chemotherapy first.
- Donors will provide bone marrow for transplant according to standard bone marrow
transplant (BMT) procedures.
- All women and half of the men will receive regular lupron doses 2 weeks before BMT to
suppress hormone function.
- All recipients will receive 4 days of radiation followed by 2-4 days of chemotherapy
before the bone marrow transplant (depending on age). Recipients will also receive
other drugs to prevent transplant rejection and other complications of transplantation.
- Recipients will be monitored in the hospital for 4 weeks after transplant with blood
tests and other studies.
- Some recipients will have an imaging study with FLT during the protocol. These imaging
studies will take place before the transplant, on days 5 and 28 after transplant, and
at a later time to be determined by the study researchers.
- Following discharge, participants will be monitored closely for up to 6 months, with
regular but less frequent followup visits for at least 5 years. Study-related
medications, including vaccinations for the new immune system, will be provided by the
National Institutes of Health during the hospital stay and after discharge.
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty [Completed]
The purpose of this study is to determine if 11. 25 and 30 mg formulations of leuprolide are
effective in treating children with Central Precocious Puberty (CPP).
Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg) [Active, not recruiting]
(A) Major 1) to compare the effectiveness of norethindrone acetate (NA) with GnRH agonist
(Lupron-Depot-3) in relieving symptoms of endometriosis, 2) to compare bone density in the
two treated groups in order to demonstrate that NA does not affect bone density; (B) Minor:
1) To compare the lipid profiles of patients in the two groups to confirm the hypothesis
that the effects of NA and GnRH agonists on lipid profiles are similar, 2) To determine
whether quality of life, assessed by questionnaire, is better in patients assigned to NA
than in patients assigned to GnRH, 3) To determine whether NA has fewer adverse effects than
A Study of Leuprolide to Treat Prostate Cancer [Completed]
To assess the efficacy and safety of 2 new formulations of leuprolide acetate 45 mg 6-month
depot, Formulation A or Formulation B, for the treatment of patients with prostate cancer. A
formulation will be deemed successful if the percentage of subjects with suppression of
testosterone to <= 50 ng/dL from Week 4 to Week 48 is not less than 87%, (the lower bound of
the 2-sided 90% confidence interval), a protocol-specified criterion.
Reports of Suspected Lupron Depot (Leuprolide) Side Effects
Hot Flush (180),
Prostate Cancer Metastatic (59),
Insomnia (58), more >>